Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … Continue reading "Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy"
What mutation is responsible for this clinical presentation in a patient with both thyroid dysfunction and chronic candidal infections?
A. Autoimmune regulator (AIRE)
B. Phosphatase and tensin homolog (PTEN)
C. Tyrosine related protein 1 (TRP1)
D. Fumarate hydratase (FH)
E. Lysosomal trafficking regulator (LYST)
To find out the correct answer and read the explanation, … 
As a former vitiligo clinical trials research fellow, I have attended more than my fair share of presentations on vitiligo. Yet, I am amazed at how each additional lecture continues to teach me new and exciting concepts and treatment options for vitiligo. Dr. Seemal Desai’s lecture at the 2022 Skin of Color Update Conference was no exception to this rule.
During the SOCU Conference held in Ne … 
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Neal Bhatia (a board-certified Dermatologist who serves as Director of Clinical Dermatology at Therapeutics Clinical Research ) about the latest with JAK inhibitors. Watch as he summarizes the most recent trials, approvals, and developments. Plus why doctors shouldn't be afraid to dive in w … 